News

MEPs greenlight EU patent
Enlarge image

RegulatoryEU

MEPs greenlight EU patent

14.12.2012 - After decades of deadlock, Europe is finally set to get a new unified patent. This week the Competitiveness Council and MEPs adopted the draft law.

Provided the draft law will be signed by at least 13 EU member states, EU patents must be only translated into three languages cutting the cost drastically. Today, two thirds of the patent cost of €36,000 is translation cost. The new unitary patent is calculated to cost a maximum of only €6,425, with the costs of translation set to range from €680 to €2,380. However, this is still twice as expensive as an US patent.  “Today’s vote is good news for the EU economy and especially for small and medium-sized enterprises (SMEs),” said MEP Bernhard Rapkay.

Italian MEP Raffaele Baldassarre, who had been leading negotiations on the new translation regime, described the current cost burden as “effectively a tax on innovation. We have to understand that there is a need out there to facilitate innovation in the EU."

Under the new scheme, patent applications will have to be made in either English, French or German – and will be made available in the same three languages. MEPs also voted to fully reimburse translation costs for EU-based SMEs, non-profit organisations, universities and public research organisations - something expected to benefit small high-tech firms in particular.Renewal fees, which are responsible for much of the overall cost of the current European system, will also be set at a level to help SMEs.

“Spain and Italy have so far opted out of the unitary patent package, but could join in the decision-making process at any time,” the Parliament says. “This procedure was used to break a deadlock, mainly due to language issues, that lasted over thirty yearsThe agreement is expected to be signed in February next year, and it will come into force on 1 January 2014 or when at least 13 member states including the UK, France and Germany have ratified it. Patents on plants have been excluded from the law, previously. The legislation still has to be formally adopted by the Council, but this will take place shortly.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/eu-parliament-okays-eu-patent.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • EVOCUTIS (UK)0.18 GBP-10.00%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%

TOP

  • KARO BIO (S)38.10 SEK2311.4%
  • TRANSGENE (F)5.08 EUR78.2%
  • BIOTECH PHARMACON (N)12.60 NOK33.1%

FLOP

  • THROMBOGENICS (B)2.90 EUR-43.0%
  • WILEX (D)2.05 EUR-37.5%
  • BIONOR PHARMA (N)1.28 NOK-37.3%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.93 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 28.08.2015